5]
The Food and Drug Administration (FDA) has issued a notification alerting physicians who prescribe
topiramate,
and their patients, to the risk of vision
loss (blindness). Acute myopia and secondary angle closure glaucoma, in a small subset of patients who take topiramate regularly, may cause transient (reversible), or permanent, loss of vision. The symptoms, which typically begin in the first month of use, include blurred vision and eye pain.